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Oral β-hydroxybutyrate increases
ketonemia, decreases visceral adipocyte
volume and improves serum lipid profile in
Wistar rats
Rennan de Oliveira Caminhotto*†, Ayumi Cristina Medeiros Komino†, Flaviane de Fatima Silva, Sandra Andreotti,
Rogério Antônio Laurato Sertié, Gabriela Boltes Reis and Fabio Bessa Lima*
Abstract
Background: Ketosis can be induced in humans and in animals by fasting or dietary interventions, such as
ketogenic diets. However, the increasing interest on the ketogenic state has motivated the development of
alternative approaches to rapidly increase ketonemia using less drastic interventions. Here, it was tested whether
oral intake of a β-hydroxybutyrate (βHB) mineral salt mixture could increase ketonemia in Wistar rats without any
other dietary changes, thereby being a useful model to study ketones effects alone on metabolism.
Methods: βHB salts were orally administered to provoke elevation in the ketonemia. Effects of this intervention
were tested acutely (by gavage) and chronically (4 weeks in drinking water). Acutely, a concomitant glucose
overload was used to suppress endogenous ketogenesis and verify whether βHB salts were really absorbed or not.
Long-term administration allowed to weekly evaluate the impact on ketonemia, blood glucose and, after 4 weeks,
on body weight, visceral fat mass, lipid blood profile, serum lipolysis products and adiponectinemia.
Results: βHB salts increased ketonemia in acute and long-term administrations, improved blood lipid profile by
raising HDL-cholesterol concentration and decreasing LDL/HDL ratio, while reduced visceral adipocyte volume.
Mean ketonemia correlated positively with HDLc and negatively with adipocyte volume and serum lipolysis
products.
Conclusions: Oral βHB can rapidly increase ketonemia and, therefore, be used as an acute and long-term animal
model of ketosis. Long-term treatment points to important beneficial effects of ketone bodies in serum lipid
concentrations and visceral fat mass. These results may help to explain the metabolic adaptations following
ketogenic diets, such as a better body fat control and a serum lipid profile improvement.
Keywords: β-hydroxybutyrate salts, Ketosis, HDL-cholesterol, Visceral fat, Experimental models
Background
It has been demonstrated that ketogenic diets have
beneficial effects to overweight [1, 2], especially in insu-
lin resistance subjects [3, 4]. Body weight and fat loss,
reduced glycemia, improvement of blood lipid profile by
increasing HDL-cholesterol and decreasing triglycerides
are among the most reproduced metabolic benefits of
ketogenic diets [5]. Also, there is evidence that blood
adiponectin, an adipokine that enhances insulin sensitiv-
ity and exerts an anti-inflammatory effects [6], can be
improved by ketogenic diets in children [7].
However, the dietary carbohydrate restriction associ-
ated with ketogenic diets by itself and the parallel in-
crease in protein/lipid consumption, as well as the state
of nutritional ketosis, are all potential mechanisms to ex-
plain the better weight control, blood lipid profile and
glycemic improvement seen in protocols which use
* Correspondence: rennanoc@icb.usp.br; fabio@icb.usp.br
†Equal contributors
Department of Physiology and Biophysics, Institute of Biomedical Sciences,
University of Sao Paulo, Av. Prof. Lineu Prestes 1524 - Ed. Biomédicas I sala
131, Butantã 05508-900, São Paulo, Brazil
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Caminhotto et al. Nutrition & Metabolism  (2017) 14:31 
DOI 10.1186/s12986-017-0184-4
ketogenic diets. In this sense, few works have dealed
with more direct and strict effects of ketones in evoking
the above clinical picture.
Exogenous administration of ketones has appeared as
an interesting tool to study and reproduce isolated ke-
tone effects. Recently, Kesl et al. [8] have tested several
natural and synthetic ketone supplements in Sprague–
Dawley rats, where ketosis was tried to be experimen-
tally induced using 1,3-butanediol, medium chain trigly-
ceride oil (MCT), a ketone ester or β-hydroxybutyrate
(βHB) mineral salts. Among the tested supplements,
only βHB mineral salts were not able to induce elevation
in ketonemia in Sprague–Dawley rats. Nevertheless,
βHB mineral salts supplementation has produced a sig-
nificant hypoglycemic effect when in combination with
MCT oil while alone decreased the body weight gain
after 4 weeks of treatment, all aspects that are influenced
by ketogenic diets.
Oral βHB salts intake has already been reported in
some previous studies: It was already effective and safely
used for the treatment of 1 year-old child with hypoke-
totic hypoglycemia caused by a fatty acid oxidation dis-
order [9]; to increase blood and cerebrospinal fluid
ketone concentrations in two infant patients with per-
sistent hyperinsulinemic hypoglycemia [10]; in the treat-
ment of multiple acyl-CoA dehydrogenase deficiency
(MADD) in three infants (a child with leukodystrophy
and two infants with cardiomyopathy) [11]; and more re-
cently, in a case of MADD-related leukodystrophy dur-
ing 3 years of treatment [12]. All of that circumstances
evidence the capacity of absorption and utilization of
oral βHB salts, at least in humans.
Therefore, considering the previous studies cited above
[9–12], we decided to retest the hypothesis that βHB
mineral salts could increase ketonemia in a different ani-
mal model (Wistar rats) and assess whether supple-
mented oral βHB mineral salts could be a model of
chronic ketosis. Also, we intended to describe whether
βHB mineral salts could influence others parameters im-
proved by ketogenic diets, as body fat and adiponectine-
mia, as well blood glucose and lipid profile.
Methods
Acute administration of βHB mineral salts
Animal procedures were performed in accordance with
the Ethics Committee on Animal Use of Institute of Bio-
medical Sciences of the University of São Paulo (18/
2016). Ten Wistar rats (8–9 weeks old), after 6 h of fast-
ing, in Zeitgeber time 0 (experimental dawn [lights on]),
were divided into two weight-matched groups: (1) βHB
salt group, which received a single dose experiment by
gavage a mixture of βHB sodium and potassium salt
form, in the concentrations of 300 mg/100 g b.w. of
βHB; and (2) 41 mg/100 g b.w. of sodium and
potassium. βHB sodium/potassium supplement were
purchase from KetoSports (KetoForce by Prototype Nu-
trition, Savind Inc - IL, USA) and consist in a solution
of approximately 50% of βHB sodium and potassium
salt. Control group received a salt mixture (NaCl/KCl)
in equivalent concentrations of sodium/potassium and
volume founded in βHB mineral salts supplement. In
addition, the two groups received a concomitant glucose
overload (75 mg/100 g b.w.) with a 50% glucose solution,
with the intent to suppress endogenous βHB formation
during the test, in order to better demonstrate whether
ketosis were really being induced by exogenous βHB
mineral salts. Tail blood was collected by small cut in tail
tip. Ketonemia and glycemia were measured at baseline
(time 0) immediately prior to gavage and at the follow-
ing times (15′, 30′, 60′, 120′). Ketonemia was measured
by Freestyle Optium XCEED (Abbott Diabetes Care,
Alameda, CA, USA) and Freestyle Optium β-Ketone
strips. Glycemia was measuring using a glucometer (One
Touch Ultra LifeScan, Milpitas, CA, USA).
Oral chronic treatment with βHB mineral salts
Wistar rats (10 weeks old) were weight paired and
assigned to control (n = 9) or βHB salts (n = 10) group,
which received a βHB mineral salts solution in drinking
water (final concentration of 4.2%) for 4 weeks. This
concentration was chosen considering a final isotonic
concentration of sodium and potassium sum (0.45% of
each one). Drinking solutions were fully available
throughout the experimental period. Ketonemia and gly-
cemia were measured weekly as described above, be-
tween Zeitgeber hours (ZT) 14–15 (experimental night)
and 0–1 (experimental morning). Body weight, food and
caloric intake (including βHB mineral salts calories)
were also measured.
Euthanasia
Fasted rats (12 h) were anesthetized with thiopental so-
dium (50 μg/g b.w.) prior to the euthanasia performed
by decapitation at ZT 13–15. Water and βHB salts solu-
tion remained available during the overnight fasting.
Blood serum was collected for biochemical analyses. The
visceral mesenteric fat pad was collected and weighed.
Determination of adipocyte volume
Adipocytes from visceral mesenteric fat pad were iso-
lated as previously described by Rodbell [13], and
fixed in 4% formaldehyde. Fixed fat cells were then
photographed (×100) using a microscope camera and
its diameter were determined using the software
Motic-Images Plus 2.0®. A mean of 100 cells was
used. Volume was calculated as previously described
by Di Girolamo et al. [14].
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Blood lipid and lipolysis products measurement
Enzymatic colorimetric assays of Triacylglycerol (TAG–
Liquiform-Labtest 87), total cholesterol (TC–Liquiform
-Labtest 76) and high-density lipoprotein fraction (HDL-
Liquiform-Labtest 13) were used to determinate blood
lipids concentrations. Low-density lipoprotein fraction
was calculated using Friedewald equation (LDL = Total
Cholesterol - HDL – [Triglycerides/5]). Glycerol and
FFA was also measured using an enzymatic-colorimetric
methods (Free Glycerol Determination Kit - Sigma-
Aldrich; Wako HR series NEFA-HR-2).
Adiponectin determination in blood and adipose tissue
Adiponectinemia and adipose tissue adiponectin protein
concentration were meansured by an adiponectin rat
ELISA kit (CUSABIO CBS-E07271r).
Statistics analysis
All data are presented as the mean ± standard error of
mean (SEM). Data analysis was performed using
GraphPad PRISM® version 5. Results were considered
significant when p < 0.05. Student’s t test was used to
compare control and treated groups. Two-Way
ANOVA was used to compare curve data. Correla-
tions were done by a linear regression of correlations
by GraphPad PRISM®. Bonferroni post hoc test was
used in all ANOVA analyses.
Results
Oral βHB impact on ketonemia
Oral administration (by gavage) of βHB salts increased
ketonemia (Fig. 1a) compared to control during all the
time tested (2 h), even during concomitant administra-
tion of glucose (Fig. 1b) intended to suppress endogen-
ous ketogenesis, showing that elevation of blood βHB
was caused by βHB exogenous supplementation. Blood
glucose, as expected, correlated negatively with βHB
levels in Control group (Fig. 1c), showing that during
the oral test the rise in glycemia was accompanied by a
reduction in ketosis. On the other hand, in βHB salt
supplemented rats, there was a disruption of this inverse
relationship because an elevation in ketonemia occurred
concomitantly with the increase in glycemia (Fig. 1d).
Chronic βHB supplementation kept ketonemia increased
throughout the day
Continues ad libitum administration of 4.2% βHB solu-
tion increased ketonemia during the two different daily
periods analyzed. Ketone bodies were weekly determined
between ZT 14–16 (lights off ) and 0–1 (lights on). The
average determination of blood ketone bodies along the
4 weeks was about 22% higher in βHB supplemented vs.
control rats in ZT 14–16 (Fig. 2b), while the ketonemia
values obtained at ZT 0–1 were 51% more elevated in
average during the 4-week period in the supplemented
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Fig. 1 Oral β-hydroxybutyrate increases ketonemia: a βHB salts significantly increased ketonemia after 30 min and sustained it for at least 2 h; b βHB salts
did not change glycemia during glucose overload (75 mg/100 g b.w.); c, d βHB salts disrupts negative correlation between glycemia and ketosis after
glucose overload (p= 0.378). n= 5 each group in all data. Two-Way ANOVA with Bonferroni post hoc test. **p< 0.01; ***p< 0.001. Data represent as
mean (SEM)
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animals (Fig. 2d). Daily intake of βHB averaged was
~600 mg/100 g body weight.
βHB mineral salts did not change body weight and caloric
intake
Continues ad libitum administration of water with 4.2%
of βHB salts did not significantly change body weight,
food consumption and caloric intake after 4 weeks of
treatment (Table 1.).
βHB mineral salts improved lipid profile
Chronic βHB supplementation improved lipid profile
after 4 weeks of treatment. HDL cholesterol increased
39% while LDL decreased 35% leading to a 49% reduc-
tion of the LDL/HDL ratio (Fig. 3a). Also, a positive cor-
relation between blood HDL cholesterol and ketone
bodies levels was found (Fig. 3b).
βHB mineral salts diminished visceral adipocytes volume
The percentage of visceral fat mass of βHB treated rats
showed a tendency to a reduction (−16%) although the dif-
ference was not statistically significant (p = 0.0529) (Fig. 4a).
However, their fat cells were 30% smaller (Fig. 4b, c and
image). Lastly, a negative correlation between visceral adi-
pocyte volume and average ketonemia were found.
βHB mineral salts did not change blood glucose and
adiponectin concentrations
In addition, βHB treatment did not influence adiponecti-
nemia at all (Fig. 5a) nor the adiponectin protein content
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Fig. 2 Continuously β-hydroxybutyrate intake increases ketonemia along the day: a, b Rats continuously drinking βHB solution had a mean increase
(22%) in ketonemia during experimental evening (ZT 14–16), while c, d a 51% increase was seen during experimental morning (ZT 0–1). n = 9-10 in all
data. Student’s t test. *p < 0.05; ***p < 0.001. Data represent as mean (SEM)
Table 1 Comparations of body weigth, food and caloric intake
Control βHB Salts P value
Initial body weight (g) 308.6 (7.6) 304.0 (6.4) 0.6466
Final body weight (g) 370.1 (9.7) 358.2 (8.9) 0.3825
Food Intake (g/day) 22.9 (1.0) 20.8 (0.6) 0.0836
Caloric Intake (Kcal/day) 94.0 (4.2) 96.6 (2.5) 0.5883
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in visceral fat (Fig. 5b). The same happened with the
blood glucose levels as a consequence of the treatment
(Fig. 5c [ZT 14–15] and d [ZT 0–1]).
Discussion
Different of the results of Kesl et al. [8] in Sprague Daw-
ley rats, this study demonstrated that acute oral βHB
mineral salts (3 g/kg) are really absorbed and reach the
systemic circulation after gavage in Wistar rats and can
rapidly increase ketonemia at levels similar to that found
during nutritional ketosis [8]. Here, ketosis was main-
tained even during concomitant glucose intake, which is
known to suppress ketogenesis due to the stimulation of
endogenous insulin secretion [15], proving that exogen-
ous ketones were the main and possibly the only source
of ketone elevation above basal values in blood during
the oral test. In the control group, on the contrary, levels
of ketone bodies slightly went down during glucose in-
gestion only. Also, in chronic treatment, despite the
ketonemia values have been lower than those achieved
during the gavage test and the ketone concentration var-
ied depending on the time of the day the ketone analysis
was done (“lights on” values > “lights off”), the ketonemia
values were always higher in the treated group. There-
fore, this protocol is a useful long-term model to in-
crease ketonemia, which is independent on carbohydrate
intake or hepatic substrate metabolic fate (i.e. beta oxi-
dation activation).
It is hypothesized that, once in bloodstream, ex-
ogenous βHB, like the endogenous ketones, is taken
up by monocarboxylic acid transporters, metabolized
to acetoacetate by D-β-hydroxybutyrate dehydrogenase
and utilized as an energy source by extrahepatic tis-
sues, such as heart, brain and muscle. However, some
important differences between exogenous βHB admin-
istration (as βHB salts) and endogenous production
(such as in fasting, ketogenic diets) are expected [16].
The strategy of oral supplementation of βHB salts
provides the entry of this substrate without the need
to synthesize it endogenously dispensing with the sev-
eral steps of its production which include an in-
creased glucagon/insulin ratio, lipolysis, transport of
lipids to the liver and beta-oxidation. Thus, by using
this protocol, it is possible to isolate ketone/ketosis
effects and investigate whether the beneficial results
frequently found during ketogenic diets are due to
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ketones directly or to other dietary variants, as higher
protein/fat intake or carbohydrate restriction.
In addition, in our model, all signaling effects βHB can
be expected, such as activation of GPR10A receptor
[17]. βHB is an endogenous ligand of GPR10A receptor,
which is also a receptor activated by niacin. Niacin is
recognized as a pharmacological agent for the treatment
of dyslipidemia, used to lower VLDL and LDL lipopro-
teins, while it raises HDL cholesterol [18]. Here, chronic
βHB administration had effects in lipid profile, notably
by raising HDL cholesterol and decreasing LDL/HDL ra-
tio, suggesting that ketones may have similar effects of
niacin on these parameters.
By sharing the same niacin receptor, this mechanism
of βHB action may explain the improvement of blood
lipids profile, since it has an inhibitory effect in lipolysis,
through Gi protein activation and a subsequent decreas-
ing release of serum lipolytic products, as free-fatty acids
(FFA) and glycerol [17]. It is known that serum FFA dir-
ectly affects other lipid transporters (VLDL/LDL lipo-
proteins) in blood, since it is a substrate for both
triglyceride and cholesterol synthesis [18].
In our study, βHB chronic treatment appears to influ-
ence serum lipolytic products because ketonemia was
negatively correlated with serum glycerol, a frequently
used marker of lipolytic activity in vivo and in vitro.
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Evidently, our data reflect a transitory influence that might
be more intense if considering other periods of the day
(remembering that euthanasia and sample collection oc-
curred at ZT 14–16, when ketonemia was lower com-
pared to the levels found at ZT 0–1), and with a
significant influence along the 4 weeks of treatment. Thus,
studies are necessary to confirm that ketone supplementa-
tion runs with low lipolytic rates along the day. Anyway, a
former study showed that a partial inhibition of adipocyte
lipolytic rates, even without changes in basal glycerol or
FFA serum concentrations, improved the animal’s meta-
bolic conditions, such as the insulin tolerance in mice
treated with hormone-sensitive lipase inhibitor [19]. It is
important to figure out that the fluctuations of serum gly-
cerol and FFA blood levels along the day are quite more
complex than their release by adipocyte through lipolysis
can explain. Glycerol concentrations also depend on its
utilization by liver, where it is utilized as a gluconeogenic
substrate. Also, above and beyond being utilized as an en-
ergy source, FFA can also be re-esterified back into triglyc-
erides by adipocytes, in a triglyceride/fatty acid futile
cycle. These points indicate that the in vivo estimation of
lipolysis is not that simple, although an inhibitory effect
by βHB can be hypothesized based on former in vitro and
in vivo studies [20, 21].
However, in addition to what might be taking place in
our protocol, a special attention is needed on the mor-
phological changes in visceral fat considering the results
from the lipid profile. The enlargement of the visceral
fat cells denotes that an increased coming of FFA is oc-
curring specifically through the mesenteric circulation
toward the portal-hepatic system, and it is an important
risk factor to ectopic liver fat deposition and hepatic
metabolic dysfunctions [22, 23]. Therefore, our results
indicate that both the smaller visceral fat cell volume
found after chronic treatment and the decreased rates of
lipolysis elicited by βHB treatment may have contributed
to improvement of serum lipid profile. To reinforce this
idea, enlarged adipocytes inversely correlate with insulin
sensitivity [24] and positively with FFA release, particu-
larly in visceral cells [25].
Regarding the HDL rise observed in βHB treated rats
(Fig. 3a), it can be hypothesized that βHB can act like
niacin by reducing the HDL catabolism and prolonging
its half-life due to an inhibition of the hepatocyte lipo-
protein uptake [26]. If the correctness of this supposition
is confirmed, it could explain our data shown in Fig. 3.
On the other hand, visceral fat deposition also has a
well-known negative correlation with HDL cholesterol
[27], and this is another way βHB treatment could be in-
directly influencing the HDLc concentrations.
An additional biological effect of GPR10A activation is
the increment of adiponectin secretion by adipocytes
[17]. Like niacin, βHB is able to induce adiponectin
secretion in primary adipocytes, although there are no
data on whether this effect also happens in vivo when
stimulated by ketones alone. On the other hand, keto-
genic diet elevated adiponectinemia in children on a trial
comparing caloric restriction and ketogenic diet [7].
Thus, these are enough evidences to lead us to
hypothesize that βHB salts supplementation could in-
crease adiponectin secretion. Furthermore, our verifica-
tion of smaller fat cells in adipose tissue of βHB
supplemented rats reinforce this supposition, since adi-
ponectin synthesis and secretion is more intense in
smaller fat cells. Fat depots containing a larger propor-
tion of small adipocytes appear to have a higher ability
to secrete adiponectin [28]. However, hyperadiponecti-
nemia was not reported in our chronic protocol.
Blood glucose was another unaffected parameter in
this study. In Kesl et al. [8], increased ketonemia was
negatively correlated with blood glucose, suggesting a
hypoglycemic effect. Indeed, Kesl et al. [8] obtained a
higher ketonemia than we got here with the exogenous
ketone supplements. Still, it is possible to note in Kesl’s
work that ketone esters and specially MCT oil, which
were the ketone supplements that most increased keto-
nemia, presented relevant suppression of blood glucose,
perhaps demonstrating the need for a greater ketosis
than that found in our experiment to achieve the same
result. However, MCT oil could induce a lower glycemia
by interfering with the dietary carbohydrate digestion
and absorption rate or by a strong reduction in food
consumption after gavage instead of its direct effect.
In our experiment, daily food consumption as well cal-
oric intake did not change significantly (−9%, p = 0.08).
Also different from βHB salts treated animals in Kesl et
al. [8], our animals did not lose weight, although the per-
centage of visceral fat mass tended to be decreased
(−16%, p = 0.0529). It should be noted that in our proto-
col rats received less βHB salts than in Kesl’s study
(~6 g/kg vs. 5–10 g/kg, respectively). The different result
between Kesl’s study and ours is possibly due to the dif-
ferent rat model in consideration (Sprague Dawley vs
Wistar) as well the way of BHB administration (daily
gavage vs drink water).
However, gathering all the results and comments plus
the decreased fat cell volume found, interesting elements
come out: ketogenic diets have already shown advan-
tages in important clinical trials, at least in short/
medium term, when carbohydrate ingestion is low
enough to increases ketonemia [1, 2]; in mice, ketogenic
diets decrease body weight and fat mass as well as a cal-
oric restriction diet, even those with a higher caloric
content per gram [29]; as Srivastava, et al. [30] reported,
a shrinkage of body fat in mice fed a ketone ester/carbo-
hydrate free diet and an increase resting energy expend-
iture and brown fat activity; rats fed on a diet enriched
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with 1,3-butanediol (a ketogenic alcohol) got a reduced
body fat mass [31]. In our protocol, differently from the
others above, since we did not make any change in ani-
mal diet and the caloric intake remained the same, an
isolated ketotic effect was reached on visceral fat mass
and tissue morphology. This data may help to explain
the metabolic advantage (i.e. a better body weight/fat
loss) found during ketogenic diets. Still, a dose-
dependent effect of βHB salts might be possible, at least
on ketonemia. For that, maybe other models of ad-
ministration would be interesting, as βHB salts on
food, as is being done by D’Agostino’s group [32].
Lastly, it is important to emphasize that although the
amount of βHB salts supplemented here in rats was a
useful tool for our experimental purposes, a transla-
tional approach to humans must be taken with care
regarding the sodium and potassium ingestion and
some concern must be considered. For example, in an
average adult man (~70 kg), to keep the same propor-
tions βHB salts, an ingestion of ~50 g of sodium and
potassium would occur which is evidently well above
the dose recommended by RDA.
Conclusions
In conclusion, we demonstrated that βHB salts oral in-
take in drinking water is useful tool to obtain a long
term model of elevated ketonemia in Wistar rats, with-
out any dietary change, as carbohydrate restriction or
high fat consumption. Also, our long term model of ele-
vated ketonemia by administration of βHB salts point to
important biological effects of ketone bodies in control
of serum lipid concentrations, particularly HDL choles-
terol and control of visceral fat mass content, specially
by contracting the adipocyte size. These results help to
explain some of metabolic adaptations that follow the
introduction of ketogenic diets, such as the improve-
ment of body control and a more effective reduction of
fat mass and serum lipid profile amelioration. This and
other ketone supplements may be helpful in the future
to complement the treatment of obesity, metabolic syn-
drome and related diseases.
Abbreviation
FFA: Free fatty acids; HDL: High density lipoprotein; LDL: Low density
lipoprotein; MADD: Multiple acyl-CoA dehydrogenase deficiency;
MCT: Medium chain triglyceride; ZT: Zeitgeber hours; βHB: Beta-
hydroxybutyrate
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